‘Flat-fixed dosing’ of chemotherapy: A concept whose time has come? Maurie Markman Editor’s Commentary Pages: 1 - 2
Two regimens of docetaxel for metastatic breast cancer Andrew D. SeidmanLarry Norton Clinical Trials Report Pages: 7 - 7
Neoadjuvant weekly paclitaxel followed by FAC Andrew D. SeidmanLarry Norton Clinical Trials Report Pages: 9 - 9
Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer Andrew D. SeidmanLarry Norton Clinical Trials Report Pages: 9 - 11
Sentinel lymph node mapping for primary breast cancer Lori L. WilsonArmando E. Giuliano OriginalPaper Pages: 12 - 17
Adjuvant chemotherapy for primary breast cancer Monica FornierClifford Hudis OriginalPaper Pages: 18 - 22
The influence of aging on the early detection, diagnosis, and treatment of breast cancer Marisa F. SiebelHyman B. Muss OriginalPaper Pages: 23 - 30
Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research Lisa E. SokolowiczWilliam J. Gradishar OriginalPaper Pages: 31 - 37
Gene expression profiling of primary breast cancer Roman RouzierPeter WagnerLajos Pusztai OriginalPaper Pages: 38 - 44
Diagnosis and treatment of primary central nervous system lymphoma Igor T. GavrilovicLauren E. Abrey OriginalPaper Pages: 47 - 54
Metastatic neurologic complications of non-Hodgkin’s lymphoma Jeanine GrierTracy Batchelor OriginalPaper Pages: 55 - 60
Neurologic complications of non-Hodgkin’s lymphoma Pierre GiglioMark R. Gilbert OriginalPaper Pages: 61 - 65
Management of primary intraocular lymphoma Stella K. KimChi-Chao ChanDana J. Wallace OriginalPaper Pages: 74 - 79
